01 Preference for Chemotherapy-Free Targeted Treatment Regimens The central nervous system lymphoma treatment market analysis highlights increasing clinical interest in targeted therapies for relapsed or refractory disease. BTK inhibitors are gaining attention as potential alternatives to conventional chemotherapy. These agents target signaling pathways involved in lymphoma cell survival. For example, ONO Pharma's Phase III IGNITE trial is evaluating tirabrutinib against rituximab plus temozolomide in patients with relapsed or refractory primary CNS lymphoma.
02 Focus on Reducing Treatment-Related Neurotoxicity Risk of neurological complications associated with whole-brain radiotherapy is influencing treatment selection for central nervous system lymphoma. Healthcare providers are increasingly considering chemotherapy-based consolidation and autologous stem cell transplantation for eligible patients. This approach aims to maintain disease control while reducing long-term cognitive impairment.
01 Supply chain disruptions are expected to have a moderate impact on the central nervous system lymphoma treatment market share, mainly due to shortages of injectable methotrexate and other chemotherapy drugs. The market is expected to experience a K-shaped recovery, as established pharmaceutical companies and major cancer centers can maintain treatment availability. Smaller hospitals remain more exposed to drug shortages and procurement delays. The market is projected to grow at a CAGR of 6.34%. Supply constraints could temporarily reduce growth, although the exact impact remains uncertain. Improved drug availability and stable pharmaceutical distribution are expected to support recovery toward the projected 6.34% growth rate.
01 The central nervous system lymphoma treatment market forecasts continued research funding for CAR T-cell immunotherapy and improved treatment delivery.
02 Key Investment and Funding Activities in Central Nervous System Lymphoma Treatment Market, 2025–2026 Company Value (USD) Details Beckman Research Institute of City of Hope USD 710,482 In September 2026, the institute received National Cancer Institute funding to continue research on intracerebroventricular CD19 CAR T-cell therapy for primary CNS lymphoma. Pennsylvania State University USD 624,845 In July 2026, the university received NIH funding for cerebrospinal fluid proteomics research involving glioblastoma and primary CNS lymphoma.
01 High Disease Recurrence Rates Drive and Adoption of Intensive Consolidation Therapy Drives Market High recurrence rate of primary central nervous system lymphoma is increasing demand for second-line treatments. Patients experiencing disease relapse require additional therapeutic interventions to control lymphoma progression. This continued need for relapse management supports central nervous system lymphoma treatment market growth.High-dose chemotherapy followed by autologous stem cell transplantation is becoming an important treatment approach for eligible patients. According to the National Cancer Institute, autologous stem cell transplantation achieved a three-year overall survival rate of 86%, compared with 71% for chemotherapy-only consolidation in a randomized trial. The clinical benefits of consolidation therapy support central nervous system lymphoma treatment market growth.
01 Limited Drug Penetration and Lack of Standardized Treatment for Relapsed CNS Lymphoma Restrain Market Expansion Several conventional lymphoma drugs cannot reach adequate concentrations in brain tissue, limiting their effectiveness. High-dose methotrexate remains a primary treatment because it can penetrate the central nervous system at therapeutic doses. However, restricted drug penetration limits treatment choices and complicates the development of effective therapies for patients with resistant disease.Absence of a standardized treatment regimen for relapsed or refractory central nervous system lymphoma is limiting market expansion. Treatment selection depends on previous therapy response and disease progression. According to the National Cancer Institute, salvage treatment options include chemotherapy, targeted agents, and radiation therapy, with no single established approach suitable for all patients.
01 Development of CAR T-Cell Immunotherapy and Integration of Cerebrospinal Fluid Liquid Biopsy Creates New Treatment Opportunities Development of CD19-directed CAR T-cell therapy presents opportunities for treating relapsed or refractory primary central nervous system lymphoma. This technology uses modified immune cells to identify and destroy lymphoma cells. According to the National Cancer Institute, a Phase I/II study reported complete responses in 6 of 12 patients receiving tisagenlecleucel. Clinical development could expand treatment options for patients who fail conventional chemotherapy.Use of cerebrospinal fluid liquid biopsy creates opportunities for improving treatment monitoring in central nervous system lymphoma. Next-generation sequencing enables the detection of circulating tumor DNA in cerebrospinal fluid, supporting the identification of residual disease and potential relapse. For example, molecular profiling can identify mutations in genes such as MYD88 and CD79B, which are commonly associated with primary CNS lymphoma.